(Total Views: 738)
Posted On: 01/14/2022 2:26:37 PM
Post# of 148900
So, a potential partner who has some sophistication - what level of confirmation of data are they looking for? Can they look at the COVID data for example and recognize the dosing issue and step up? Or see the HIV data and realize the BLA is just a formality? Or even look at the initial NASH data and make a leap of faith?
That’s something I’ve wondered for a long time - if we all know the potential of the drug, and their business is finding the next great drug, why has no one stepped up? The answer many state is that we haven’t gotten a ‘reasonable” offer. Why not? In this frothy environment for pharma, why has no one come after one of the indications aggressively?
That’s something I’ve wondered for a long time - if we all know the potential of the drug, and their business is finding the next great drug, why has no one stepped up? The answer many state is that we haven’t gotten a ‘reasonable” offer. Why not? In this frothy environment for pharma, why has no one come after one of the indications aggressively?
(1)
(0)Scroll down for more posts ▼
